A company developing small molecule therapeutics targeting DNA Damage Response (DDR) in order to treat patients with a broad range of cancers has its first assay development customer.
Related Keywords
Artios Pharma , Andrew Newland , , Markets Amp Regulations , Preclinical Research , Hasei Ii , Essay , Dancer , Clinical Trials , Ncology , Research ,
vimarsana.com © 2020. All Rights Reserved.